- Report
- July 2023
- 89 Pages
China
From €1735EUR$1,800USD£1,484GBP
- Report
- March 2021
Japan, United States, ... Japan, United States, Europe
From €916EUR$950USD£783GBP
- Report
- February 2020
Japan, United States, ... Japan, United States, Europe
From €916EUR$950USD£783GBP
- Report
- September 2019
Global
From €5177EUR$5,370USD£4,428GBP
- Report
- April 2023
- 147 Pages
Global
From €5784EUR$5,999USD£4,946GBP
- Report
- March 2023
- 147 Pages
Global
From €5784EUR$5,999USD£4,946GBP
The Cervical Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat cervical cancer. Cervical cancer is a type of cancer that affects the cells of the cervix, the lower part of the uterus. Cervical cancer drugs are used to treat the disease, either by killing the cancer cells or by slowing their growth.
Cervical cancer drugs are typically administered orally, intravenously, or intramuscularly. Commonly used drugs include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy drugs are used to kill cancer cells, while targeted therapy drugs are used to block the growth of cancer cells. Immunotherapy drugs are used to boost the body's immune system to fight the cancer.
Some of the major companies in the Cervical Cancer Drugs market include Bristol-Myers Squibb, Merck & Co., Pfizer, AstraZeneca, and Eli Lilly. These companies are involved in the development, manufacture, and sale of cervical cancer drugs. Show Less Read more
